glp 1 patents June 2024 Patent Highlights: GLP-1R Agonists, Polθ Inhibitors, Non-Ab PD-L1 Inhibitors, and More! GLP-1 Patent Landscape: Who Leads
Description
LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose
Peer-reviewed publications, data-sharing initiatives, and interdisciplinary symposia facilitate knowledge dissemination and foster a culture of continuous learning
Peripherally administered GLP-1 thus indirectly activates neurons of the amygdala
The funders had no role in the design of the study
